Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
588 Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: post hoc analysis of the costs of grade ≥3 adverse events (AEs)
Compose a Response to This Article
Other responses
No responses have been published for this article.
